U.S. markets open in 8 hours 3 minutes

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
56.66+0.66 (+1.18%)
At close: 4:00PM EST

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
http://www.acadia-pharm.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees580

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen R. DavisCEO & Director1.36M7.98M1961
Dr. Srdjan R. StankovicPres1.23MN/A1957
Ms. Elena H. Ridloff C.F.A., CFAExec. VP & CFO689.09k1.22M1980
Mr. Austin D. KimExec. VP, Gen. Counsel & Sec.700.8k480.9k1964
Mr. Michael J. YangExec. VP & Chief Commercial Officer810.41k1.62M1962
Mr. James K. KiharaVP, Corp. Controller & Principal Accounting OfficerN/AN/A1980
Mr. Bob MischlerSr. VP of Strategy & Technology OperationsN/AN/AN/A
Dr. Eliseo Oreste SalinasSr. VP, Chief Scientific Officer & Head of External InnovationN/AN/A1956
Mr. Mark C. JohnsonVP of Investor RelationsN/AN/AN/A
Mr. Ryan E. BrownChief Compliance Officer & VPN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Corporate Governance

ACADIA Pharmaceuticals Inc.’s ISS Governance QualityScore as of November 1, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.